Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Phyllis J Goodman

Showing results (41-50 of 157) with videos related to

Pageof 16
Sort By:
American Journal of Epidemiology|October 24, 2008
Serum steroid and sex hormone-binding globulin concentrations and the risk of incident benign prostatic hyperplasia: results from the prostate cancer prevention trialAlan R Kristal, Jeannette M Schenk, YoonJu Song, et al.
Journal of the National Cancer Institute|August 17, 2006
Effect of finasteride on the sensitivity of PSA for detecting prostate cancerIan M Thompson, Chen Chi, Donna Pauler Ankerst, et al.
The New England Journal of Medicine|January 24, 2019
Long-Term Effects of Finasteride on Prostate Cancer MortalityPhyllis J Goodman, Catherine M Tangen, Amy K Darke, et al.
Free Radical Biology & Medicine|March 26, 2016
Effect of long-term vitamin E and selenium supplementation on urine F2-isoprostanes, a biomarker of oxidative stressKristin A Guertin, Rachael K Grant, Kathryn B Arnold, et al.
Frontiers in Oncology|January 31, 2022
Associations Between Polymorphisms in Genes Related to Oxidative Stress and DNA Repair, Interactions With Serum Antioxidants, and Prostate Cancer Risk: Results From the Prostate Cancer Prevention TrialZhihong Gong, Mary E Platek, Cathee Till, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|November 6, 2009
Men with low serum cholesterol have a lower risk of high-grade prostate cancer in the placebo arm of the prostate cancer prevention trialElizabeth A Platz, Cathee Till, Phyllis J Goodman, et al.
Cancer Causes & Control : CCC|February 6, 2010
Intra-individual variation in serum C-reactive protein over 4 years: an implication for epidemiologic studiesElizabeth A Platz, Siobhan Sutcliffe, Angelo M De Marzo, et al.
Urology|May 28, 2014
Prostate Cancer Prevention Trial risk calculator 2.0 for the prediction of low- vs high-grade prostate cancerDonna P Ankerst, Josef Hoefler, Sebastian Bock, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|February 10, 2010
Human papillomavirus types 16, 18, and 31 serostatus and prostate cancer risk in the Prostate Cancer Prevention TrialSiobhan Sutcliffe, Raphael P Viscidi, Cathee Till, et al.
Journal of the National Cancer Institute|August 28, 2016
Long-term Consequences of Finasteride vs Placebo in the Prostate Cancer Prevention TrialJoseph M Unger, Cathee Till, Ian M Thompson, et al.
Pageof 16

Showing results (41-50 of 157) with videos related to

Sort By:
Pageof 16
American Journal of Epidemiology|October 24, 2008
Serum steroid and sex hormone-binding globulin concentrations and the risk of incident benign prostatic hyperplasia: results from the prostate cancer prevention trialAlan R Kristal, Jeannette M Schenk, YoonJu Song, et al.
Journal of the National Cancer Institute|August 17, 2006
Effect of finasteride on the sensitivity of PSA for detecting prostate cancerIan M Thompson, Chen Chi, Donna Pauler Ankerst, et al.
The New England Journal of Medicine|January 24, 2019
Long-Term Effects of Finasteride on Prostate Cancer MortalityPhyllis J Goodman, Catherine M Tangen, Amy K Darke, et al.
Free Radical Biology & Medicine|March 26, 2016
Effect of long-term vitamin E and selenium supplementation on urine F2-isoprostanes, a biomarker of oxidative stressKristin A Guertin, Rachael K Grant, Kathryn B Arnold, et al.
Frontiers in Oncology|January 31, 2022
Associations Between Polymorphisms in Genes Related to Oxidative Stress and DNA Repair, Interactions With Serum Antioxidants, and Prostate Cancer Risk: Results From the Prostate Cancer Prevention TrialZhihong Gong, Mary E Platek, Cathee Till, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|November 6, 2009
Men with low serum cholesterol have a lower risk of high-grade prostate cancer in the placebo arm of the prostate cancer prevention trialElizabeth A Platz, Cathee Till, Phyllis J Goodman, et al.
Cancer Causes & Control : CCC|February 6, 2010
Intra-individual variation in serum C-reactive protein over 4 years: an implication for epidemiologic studiesElizabeth A Platz, Siobhan Sutcliffe, Angelo M De Marzo, et al.
Urology|May 28, 2014
Prostate Cancer Prevention Trial risk calculator 2.0 for the prediction of low- vs high-grade prostate cancerDonna P Ankerst, Josef Hoefler, Sebastian Bock, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|February 10, 2010
Human papillomavirus types 16, 18, and 31 serostatus and prostate cancer risk in the Prostate Cancer Prevention TrialSiobhan Sutcliffe, Raphael P Viscidi, Cathee Till, et al.
Journal of the National Cancer Institute|August 28, 2016
Long-term Consequences of Finasteride vs Placebo in the Prostate Cancer Prevention TrialJoseph M Unger, Cathee Till, Ian M Thompson, et al.
Pageof 16